Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.
Rhea-AI Summary
Dyne Therapeutics (Nasdaq:DYN) expanded its non-dilutive senior secured term loan facility with Hercules Capital to provide up to $400 million in total borrowing capacity.
The amendment adds $125 million of potential funding, with $50 million funded at closing and up to $200 million remaining available to support DMD and DM1 programs.
Positive
- Total Hercules Capital term loan facility increased to up to $400 million
- Additional $125 million in borrowing capacity secured under the amendment
- $50 million funded immediately upon execution of the amendment
- New $50 million tranche available at Dyne’s option upon milestone achievement
- Final term loan tranche increased by $25 million to up to $75 million
- Dyne has borrowed an aggregate of $200 million while retaining access to up to $200 million more
Negative
- None.
News Market Reaction – DYN
In the Jun 17 session, DYN gained 6.25%, reflecting a notable positive market reaction. Argus tracked a peak move of +9.0% during that session. Our momentum scanner triggered 43 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 03 | ACHIEVE REC enrollment | Positive | +4.3% | Completed enrollment of 71-participant REC cohort in ACHIEVE DM1 trial. |
| May 26 | BLA submission | Positive | +4.5% | Filed BLA seeking Accelerated Approval for z-rostudirsen in exon 51 DMD. |
| May 20 | Inducement grants | Neutral | -1.1% | Granted stock options and RSUs to new employees under inducement plan. |
| May 20 | Phase 3 trial start | Positive | +6.3% | Initiated global Phase 3 FORZETTO trial of z-rostudirsen in DMD. |
| May 13 | Investor conferences | Neutral | +0.4% | Announced participation in multiple healthcare investor conferences. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent pipeline and regulatory milestones for DMD and DM1 have generally seen positive price reactions, while equity and compensation-related items have had more muted or negative responses.
Over the last month, Dyne reported several key milestones. On May 13, it outlined upcoming healthcare conferences. On May 20, it initiated the Phase 3 FORZETTO trial for z-rostudirsen and separately disclosed inducement grants. A BLA submission for z-rostudirsen in DMD followed on May 26. By June 3, Dyne completed enrollment of 71 participants in the ACHIEVE REC for z-basivarsen in DM1. Today’s debt facility expansion supports advancing these programs toward anticipated launches.
Key Terms
senior secured term loan facility financial
term loan tranche financial
Duchenne muscular dystrophy medical
myotonic dystrophy type 1 medical
exon 51 medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Up to
-
WALTHAM, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has entered into an amendment to its non-dilutive senior secured term loan facility with Hercules Capital, Inc. (NYSE: HTGC), a leader in customized debt financing for companies in the life sciences and technology-related markets. The transaction further strengthens the company’s balance sheet as it advances zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) for exon 51 Duchenne muscular dystrophy (DMD) and zeleciment basivarsen (z-basivarsen, also known as DYNE-101) for myotonic dystrophy type 1 (DM1) through critical clinical and regulatory milestones.
“As we continue to focus on diligent execution against our clinical and regulatory objectives, we are pleased to deepen our partnership with Hercules,” said Erick Lucera, chief financial officer of Dyne. “This additional access to capital enhances our financial flexibility as we prepare for two potential U.S. launches in the next two years and continue on our mission to deliver functional improvement for individuals living with rare neuromuscular diseases.”
“Hercules is proud to be expanding our support of Dyne as they prepare for the potential approval and commercial launches of z-rostudirsen and z-basivarsen,” said R. Bryan Jadot, Senior Managing Director and Group Head at Hercules Capital. “Our increased commitment reflects our strong conviction in Dyne’s programs and our unique ability to support innovative life sciences companies at transformative stages of development.”
Under the terms of the amendment,
About Dyne Therapeutics
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.
About Hercules Capital
Hercules Capital, Inc. (NYSE: HTGC) is the leading and largest specialty finance company focused on providing senior secured venture growth loans to high-growth, innovative venture capital-backed companies in a broad variety of technology and life sciences industries. Since inception (December 2003), Hercules has committed more than
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Dyne’s strategy, future operations, prospects and plans, objectives of management, the ability of Dyne to achieve any of the specified clinical, regulatory or commercial milestones under its loan agreement with Hercules Capital, as amended, the potential of the FORCE platform, the potential of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) and zeleciment basivarsen (z-basivarsen, also known as DYNE-101), the anticipated timelines for potential commercial launch of z-rostudirsen and z-basivarsen, the availability of expedited approval pathways for z-rostudirsen and z-basivarsen, expectations regarding the outcome of interactions with regulatory authorities, and the sufficiency of Dyne’s cash resources for the period anticipated, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” “will,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: Dyne’s ability to comply with the covenants and other obligations under its loan agreement with Hercules Capital; uncertainties inherent in the identification and development of product candidates, including the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and Dyne’s ability to enroll patients in clinical trials; whether results from preclinical studies and data from clinical trials will be predictive of the final results of the clinical trials or other trials; whether data from clinical trials will support submission for regulatory approvals; uncertainties as to the FDA’s and other regulatory authorities’ interpretation of the data from Dyne's clinical trials and acceptance of Dyne's clinical programs and as to the regulatory approval process for Dyne's product candidates; whether Dyne’s cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in Dyne’s filings with the Securities and Exchange Commission (SEC), including the company’s most recent Form 10-Q and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne’s views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne’s views as of any date subsequent to the date of this press release.
Contacts:
Investors
Mia Tobias
ir@dyne-tx.com
781-317-0353
Media
Stacy Nartker
snartker@dyne-tx.com
781-317-1938
